79 results
Page 3 of 4
6-K
EX-99.1
cks4m5
8 Sep 21
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
7:30am
6-K
EX-99
qju1ii v8oklexvnjw
10 Aug 21
Current report (foreign)
7:31am
6-K
EX-99.1
bx10bx47fckezgr cho
10 Aug 21
InflaRx Announces Positive Data from Second Interim Analysis
7:30am
6-K
EX-99.2
mlwxs
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.3
xkwypee0 9md9xmy8k
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
6y46lxp3b33msgrcj4
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
e8bfrv
8 Jun 21
Current report (foreign)
7:30am
6-K
EX-99.1
fh47i5w21i5b
21 May 21
Tony Gibney Joins InflaRx Board of Directors
8:16am
6-K
EX-99.3
sxycdwrk
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.2
80ziqynei6
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
qhe2f
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
emnrst661
11 May 21
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
4:30pm
6-K
EX-99.1
l750iixdennr8smy
3 May 21
Current report (foreign)
4:15pm
6-K
EX-99.1
00b9 bppalx3xzm
15 Apr 21
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study
7:30am
6-K
EX-99.1
cx7wx0jvpugy14
25 Mar 21
InflaRx Reports Full Year 2020 Financial & Operating Results
7:28am
424B5
tc4rcod2cw9a36m9k
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
730esj48tm
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
6tgcljf7mj3hj1
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.1
zonxa3fn8zuvu94
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am